Bristol Myers Squibb Company $BMY Stock Sold by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. reduced its position in Bristol Myers Squibb Company (NYSE:BMY) by 0.6% in the 3rd quarter, HoldingsChannel reports. The firm owned 7,200,298 shares of the biopharmaceutical company’s stock after selling 44,332 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Bristol Myers Squibb were worth $449,299,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Primecap Management Co. CA acquired a new position in Bristol Myers Squibb during the second quarter worth approximately $1,436,115,000. Legal & General Group Plc bought a new stake in Bristol Myers Squibb in the second quarter valued at approximately $980,862,000. BlackRock Inc. lifted its position in shares of Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after buying an additional 8,702,106 shares during the last quarter. State Street Corp lifted its position in shares of Bristol Myers Squibb by 7.3% in the second quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock valued at $6,093,755,000 after buying an additional 7,192,724 shares during the last quarter. Finally, Caisse de depot et placement du Quebec bought a new position in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $243,646,000. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Up 5.0%

Bristol Myers Squibb stock opened at $61.76 on Wednesday. The stock has a market cap of $126.15 billion, a P/E ratio of 13.60, a P/E/G ratio of 0.29 and a beta of 0.19. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $68.64. The company’s 50-day moving average price is $63.39 and its two-hundred day moving average price is $60.28.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same period last year, the business posted $1.46 earnings per share. The business’s revenue for the quarter was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, analysts expect that Bristol Myers Squibb Company will post 6.77 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.1%. The ex-dividend date of this dividend is Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.51%.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on BMY. Cantor Fitzgerald decreased their target price on Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating on the stock in a report on Thursday, October 8th. Truist Financial restated a “buy” rating and issued a $70.00 price target (up from $65.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Leerink Partners downgraded Bristol Myers Squibb from an “outperform” rating to a “market perform” rating and cut their price target for the company from $73.00 to $59.00 in a report on Monday, October 5th. William Blair reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, October 12th. Finally, Rothschild & Co Redburn lifted their price objective on shares of Bristol Myers Squibb from $51.00 to $53.00 and gave the stock a “neutral” rating in a research report on Thursday, October 8th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $64.88.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: RBC expects Bristol Myers Squibb to exceed third-quarter revenue estimates, reinforcing optimism ahead of the company’s earnings report. RBC expects a third-quarter revenue beat for Bristol Myers Squibb stock
• Positive Sentiment: Bristol Myers Squibb is scheduled to present new oncology data at ESMO 2026, including results for pumitamig, izalontamab brengitecan (iza-bren), and the Opdivo-Yervoy combination. Positive data could support the company’s pipeline and long-term growth outlook. Bristol Myers Squibb Heads To ESMO 2026 With New Oncology Data
• Positive Sentiment: Analysts and financial commentators continue to highlight BMY’s relatively low valuation, substantial free-cash-flow generation, and dividend yield of approximately 4.3%. Goldman Sachs also upgraded the stock, adding to bullish sentiment. Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? Bristol Myers Squibb Upgraded at The Goldman Sachs Group
• Neutral Sentiment: Investor attention across the pharmaceutical sector is elevated ahead of cancer-drug presentations, with Moderna also attracting buying interest. That broader oncology focus may be helping sentiment toward BMY, although the Moderna catalyst is not directly related to Bristol Myers Squibb. Moderna Jumps While Melanoma Vaccine Data Looms
• Negative Sentiment: The company still faces the challenge of replacing revenue from aging blockbuster medicines. Upcoming ESMO results could either validate its pipeline strategy or increase concerns about future growth. Bristol Myers vs. Eli Lilly: Is BMY’s Deep Valuation Discount Hiding an Opportunity?

Insiders Place Their Bets

In related news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. The trade was a 2.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.